⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of HansBiomed Corp. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
HansBiomed Corp.
↗Seoul, South Korea
HansBiomed is a South Korean biotechnology company specializing in tissue engineering, medical devices, and aesthetic products. Founded in 1999, it was the first company in Korea to receive government approval to establish a tissue bank, positioning itself as a leader in human tissue transplantation and regenerative medicine.
The company's diverse portfolio includes allograft bone and skin products, silicone breast implants (BellaGel), PDO lifting threads (MINT Lift), and various hair transplant and scar management solutions. HansBiomed operates globally with multiple subsidiaries and research centers, focusing on R&D to advance medical technologies in aesthetic and reconstructive surgery.
CLASSIFICATION
Company Type:MedTech
Therapeutic Areas:-
Industry:Medical Devices
Sub-Industry:Aesthetic Medicine & Tissue Engineering
SIZE & FINANCIALS
Employees:201-500
Revenue:$50M-$100M
Founded:1999
Ownership:public
Status:operating
FUNDING
Total Raised:$0
STOCK
Exchange:KOSDAQ
Ticker:042520
Market Cap:~$0.42B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Tissue Engineering, Medical Devices, Biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:HansBiomed USA, Shanghai Hansbiomed, HansBiomed Thailand, HansBiomed Mexico, HansBiomed Colombia
Key Partnerships:Hugel (Collaboration on ECM-based injectable products)
COMPETITION
Position:Challenger
Competitors:Mentor Worldwide (J&J), Allergan (AbbVie), Establishment Labs, POLYTECH Health & Aesthetics, L&C BIO
LEADERSHIP
Key Executives:
Geun Young Kim - CEO
LINKS
Website:hansbiomed.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with HansBiomed Corp.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.